Vir Biotechnology Prices $8.50 Equity Offering; About $141M Net Proceeds, Goldman Leads
VIR has more than doubled off its 52-week low of $4.155 on elevated volume (7.0× avg).
Summary
Vir Biotechnology has priced an equity offering of 17,647,059 shares at $8.50 per share, expecting to raise approximately $141.1 million in net proceeds, potentially increasing to $162.3 million if the underwriters exercise their option. This offering, led by Goldman Sachs, represents a material dilution for existing shareholders, equivalent to over 10% of the company's current market capitalization, and is priced below the recent trading price of $9.25. While providing capital for operations and growth, the significant dilution and discounted pricing are likely to exert downward pressure on the stock. Investors will be watching for the closing of the offering on February 27, 2026, and further details on the use of proceeds.
At the time of this announcement, VIR was trading at $9.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $4.16 to $10.94. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Unknown.